MW 151
Alternative Names: MW-151; MW01-2-151SRMLatest Information Update: 28 Nov 2023
At a glance
- Originator Northwestern University
- Developer ImmunoChem Therapeutics
- Class Antidementias; Neuroprotectants; Small molecules
- Mechanism of Action Cytokine inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cognition disorders
- No development reported Alzheimer's disease; Multiple sclerosis; Traumatic brain injuries; Unspecified
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (PO, Capsule)
- 28 Nov 2023 No recent reports of development identified for preclinical development in Multiple-sclerosis in USA (PO)
- 28 Nov 2023 No recent reports of development identified for preclinical development in Traumatic-brain-injuries in USA (PO)